Published in Cancer Res on April 01, 1995
A platform for rapid exploration of aging and diseases in a naturally short-lived vertebrate. Cell (2015) 2.65
Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol (1997) 1.75
Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis. Mol Cell Biol (2003) 1.58
Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol (1997) 1.36
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer (2010) 1.33
Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol (1999) 1.25
Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol (1999) 1.08
Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol (1998) 1.04
Polymorphism of p16INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma. World J Gastroenterol (2000) 1.03
Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs (2001) 0.95
Role of cell cycle regulators in lung carcinogenesis. Cell Adh Migr (2010) 0.93
Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins. J Cancer Res Clin Oncol (2009) 0.90
Methylation and mutation analysis of p16 gene in gastric cancer. World J Gastroenterol (2003) 0.90
Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer (1997) 0.87
Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein. Protein Sci (1996) 0.86
Transcriptional repression by RB-E2F and regulation of anchorage-independent survival. Mol Cell Biol (2001) 0.85
Cytotoxic effects of fascaplysin against small cell lung cancer cell lines. Mar Drugs (2014) 0.82
Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer (1999) 0.81
Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels. Nucleic Acid Ther (2014) 0.80
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. Cancer Biol Ther (2013) 0.80
Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin. Cancer Cell Int (2013) 0.79
Sequential loss of heterozygosity in the progression of squamous cell carcinoma of the lung. Br J Cancer (1998) 0.78
Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases. Ann Surg (2000) 0.78
Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma. PLoS One (2013) 0.77
A Comprehensive and System Review for the Pharmacological Mechanism of Action of Rhein, an Active Anthraquinone Ingredient. Front Pharmacol (2016) 0.76
Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development. Proc Natl Acad Sci U S A (2003) 0.75
Histone deacetylase 1 and 2 are essential for murine neural crest proliferation, pharyngeal arch development and craniofacial morphogenesis. Dev Dyn (2017) 0.75
Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 38.75
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 23.17
Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev (2001) 21.82
p21 is a universal inhibitor of cyclin kinases. Nature (1993) 15.55
Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 15.32
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (1995) 8.53
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (1994) 8.22
Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (1995) 7.25
Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet (2001) 5.84
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med (1999) 4.15
p21-containing cyclin kinases exist in both active and inactive states. Genes Dev (1994) 4.08
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (1989) 3.80
Myc activates telomerase. Genes Dev (1998) 3.74
Construction of an improved host strain for two hybrid screening. Nucleic Acids Res (1994) 3.43
Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (1994) 3.21
Twist is a potential oncogene that inhibits apoptosis. Genes Dev (1999) 3.14
A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10
The rest is silence. RNA (2001) 3.07
[Yield of laboratory tests in the detection of excessive drinkers in the work place]. Med Clin (Barc) (1993) 2.64
Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A (1994) 2.64
Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res (2001) 2.37
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol (2005) 2.18
Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol (2000) 2.17
Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst (1999) 2.10
Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene (1995) 2.05
DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci U S A (2001) 2.00
Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene (1999) 2.00
Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A (1993) 1.95
Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem (2000) 1.88
The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I. J Biol Chem (1999) 1.84
Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene (2009) 1.78
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2008) 1.78
Plant cells contain a novel member of the retinoblastoma family of growth regulatory proteins. EMBO J (1996) 1.70
Mutations associated with familial melanoma impair p16INK4 function. Nat Genet (1995) 1.69
Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A (1996) 1.68
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol (1999) 1.62
Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature (1998) 1.61
p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med (1998) 1.55
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer (2006) 1.53
Induction of senescence by oncogenic Ras. Methods Enzymol (2001) 1.52
Design of a retroviral-mediated ecdysone-inducible system and its application to the expression profiling of the PTEN tumor suppressor. Proc Natl Acad Sci U S A (2001) 1.49
Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood (2001) 1.49
p53-independent role of MDM2 in TGF-beta1 resistance. Science (1998) 1.48
Small RNA silencing pathways in germ and stem cells. Cold Spring Harb Symp Quant Biol (2009) 1.48
The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J (1999) 1.48
[Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi (1987) 1.48
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A (1989) 1.45
Evolutionary relationships among proteins in the phytohemagglutinin-arcelin-alpha-amylase inhibitor family of the common bean and its relatives. Plant Mol Biol (1994) 1.44
In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother (2001) 1.44
The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med (2000) 1.43
Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol (1996) 1.41
[Diffuse mediastinal lipomatosis and exogenous obesity]. Rev Clin Esp (1993) 1.39
Fahr's syndrome presenting with pure and progressive presenile dementia. Neurol Sci (2005) 1.39
Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood (1992) 1.39
Growth suppression of esophageal cancer cells by p16INK4 and p15INK4B in vitro. Cancer J Sci Am (2006) 1.39
Risky immortalization by telomerase. Nature (2000) 1.38
Equine Borna disease in Japan. Vet Rec (2001) 1.38
[Non-Hodgkin's lymphomas associated with the acquired immunodeficiency syndrome. A multicenter clinical study of 77 cases]. Med Clin (Barc) (1995) 1.38
Functional interaction of p53 and BLM DNA helicase in apoptosis. J Biol Chem (2001) 1.37
Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene (2006) 1.32
Transcription and cap trimethylation of a nematode spliced leader RNA in a cell-free system. Proc Natl Acad Sci U S A (1990) 1.27
Identification and characterization of receptors for granulocyte colony-stimulating factor on human placenta and trophoblastic cells. Proc Natl Acad Sci U S A (1989) 1.26
Molecular evolution of piRNA and transposon control pathways in Drosophila. Cold Spring Harb Symp Quant Biol (2010) 1.21
Interaction of the bacteriophage phi 29 protein p6 with double-stranded DNA. Proc Natl Acad Sci U S A (1988) 1.21
A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature (1987) 1.20
Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies. Invest Ophthalmol Vis Sci (1999) 1.18
Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol (1995) 1.17
Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J (1997) 1.16
A minor outer capsid protein, P9, of Rice dwarf virus. Arch Virol (2003) 1.16
The nematode spliced leader RNA participates in trans-splicing as an Sm snRNP. EMBO J (1990) 1.14
Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export pathway. J Biol Chem (2001) 1.13
Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol Biol Cell (1996) 1.12
SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ (2010) 1.10
17Beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. Eur J Pharmacol (1997) 1.10
Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene (2001) 1.10
The C-terminal SH3 domain of the mouse c-Crk protein negatively regulates tyrosine-phosphorylation of Crk associated p130 in rat 3Y1 cells. Oncogene (1994) 1.09
Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging (Albany NY) (2013) 1.09
p53-dependent association between cyclin G and the B' subunit of protein phosphatase 2A. Mol Cell Biol (1996) 1.08
p53 Modulates the exonuclease activity of Werner syndrome protein. J Biol Chem (2001) 1.07
Genetic dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression. Oncogene (2006) 1.07
Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene (1997) 1.07
Purification and characterization of the alpha-tocopherol transfer protein from rat liver. FEBS Lett (1991) 1.07
Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res (1995) 1.06
Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res (1987) 1.06
SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene (2012) 1.05